Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) EPS (Weighted Average and Diluted) (2022 - 2025)

Dianthus Therapeutics has reported EPS (Weighted Average and Diluted) over the past 4 years, most recently at -$0.97 for Q3 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.97 for Q3 2025, down 31.08% from a year ago — trailing twelve months through Sep 2025 was -$3.5 (down 148.88% YoY), and the annual figure for FY2024 was -$2.55, up 69.82%.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$0.97 at Dianthus Therapeutics, down from -$0.89 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for DNTH hit a ceiling of $8.95 in Q4 2023 and a floor of -$31.62 in Q4 2022.
  • Median EPS (Weighted Average and Diluted) over the past 4 years was -$0.82 (2024), compared with a mean of -$3.3.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 128.3% in 2023, while the deepest fall reached 1976.92% in 2023.
  • Dianthus Therapeutics' EPS (Weighted Average and Diluted) stood at -$31.62 in 2022, then surged by 128.3% to $8.95 in 2023, then crashed by 109.16% to -$0.82 in 2024, then fell by 18.29% to -$0.97 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.97 (Q3 2025), -$0.89 (Q2 2025), and -$0.82 (Q1 2025) per Business Quant data.